Standards & Regulation

How will pharmacovigliance in the UK and Europe be affected by Brexit?

What are biosynthetic cannabinoids? And what do they mean for pharma?

Neil Mahapatra gives the story behind a partnership with Oxford University to develop cannabinoid medicines

Data management is a key factor for success with serialization

Drug costs could be lowered if review and approval processes were much faster

How important is pharmacovigilance in the post-market safety of drugs?

Will a pilot project to prequalify “generic” biologics improve safe access to medicines?

With big regulatory changes on the horizon, RAPS invests in Europe.

We forge ahead to celebrate the fantastic individuals involved in bettering the pharma industry.

We Sit Down With Daniel O'Connor, Medical Assessor at the MHRA, UK.